Search

Your search keyword '"Beaufort, Corine M."' showing total 21 results
Start Over Author "Beaufort, Corine M."
21 results on '"Beaufort, Corine M."'

2. CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients

Author

Isebia, Khrystany T., Mostert, Bianca, Belderbos, Bodine P.S., Buck, Stefan A.J., Helmijr, Jean C.A., Kraan, Jaco, Beaufort, Corine M., Van, Mai N., Oomen - de Hoop, Esther, Sieuwerts, Anieta M., van IJcken, Wilfred F.J., van den Hout - van Vroonhoven, Mirjam C.G.N., Brouwer, Rutger W.W., Oole, Edwin, Hamberg, Paul, Haberkorn, Brigitte C.M., Helgason, Helgi H., de Wit, Ronald, Sleijfer, Stefan, Mathijssen, Ron H.J., Martens, John W.M., Jansen, Maurice P.H.M., van Riet, Job, and Lolkema, Martijn P.

Published
2022
Full Text
View/download PDF

4. Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2 -Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.

Author

Meijer, Titia G., Martens, John W. M., Prager-van der Smissen, Wendy J. C., Verkaik, Nicole S., Beaufort, Corine M., van Herk, Stanley, Robert-Finestra, Teresa, Hoogenboezem, Remco M., Ruigrok-Ritstier, Kirsten, Paul, Maarten W., Gribnau, Joost, Bindels, Eric M. J., Kanaar, Roland, Jager, Agnes, van Gent, Dik C., and Hollestelle, Antoinette

Subjects
OVARIAN tumors, GENETIC mutation, HOMOGRAFTS, SEQUENCE analysis, BRCA genes, FUNCTIONAL status, EARLY detection of cancer, CELLS, GENE expression profiling, DESCRIPTIVE statistics, METHYLATION, RESEARCH funding, CELL lines, BREAST tumors
Abstract

Simple Summary: Cancer cells from patients who carry a disease-causing BRCA1 or BRCA2 mutation are incapable of repairing double-strand DNA breaks via the homologous recombination (HR) repair pathway. As a consequence, these patients respond to platinum-based chemotherapy and Poly-[ADP-Ribose]-Polymerase inhibitors (PARPi). However, using a functional read-out for HR, we show that not all HR-deficient cell lines carry a BRCA1/2 mutation. Moreover, the majority of BRCA1/2-mutant cell lines are HR proficient, highlighting the importance of measuring the functional HR status. For almost all of the BRCA1/2-mutant HR proficient cell lines, we could explain the discrepant HR status. The observed reversion mechanisms predominantly acted on restoring the BRCA1 or BRCA2 mutation directly. Taken together, our results indicate that only determining BRCA1/2 mutation status may not suffice for selecting patients for platinum-based chemotherapy or PARPi. Moreover, for experimental approaches cell line functionality of HR should be assessed beforehand. Tumors with a pathogenic BRCA1/2 mutation are homologous recombination (HR)-deficient (HRD) and consequently sensitive to platinum-based chemotherapy and Poly-[ADP-Ribose]-Polymerase inhibitors (PARPi). We hypothesized that functional HR status better reflects real-time HR status than BRCA1/2 mutation status. Therefore, we determined the functional HR status of 53 breast cancer (BC) and 38 ovarian cancer (OC) cell lines by measuring the formation of RAD51 foci after irradiation. Discrepancies between functional HR and BRCA1/2 mutation status were investigated using exome sequencing, methylation and gene expression data from 50 HR-related genes. A pathogenic BRCA1/2 mutation was found in 10/53 (18.9%) of BC and 7/38 (18.4%) of OC cell lines. Among BRCA1/2-mutant cell lines, 14/17 (82.4%) were HR-proficient (HRP), while 1/74 (1.4%) wild-type cell lines was HRD. For most (80%) cell lines, we explained the discrepancy between functional HR and BRCA1/2 mutation status. Importantly, 12/14 (85.7%) BRCA1/2-mutant HRP cell lines were explained by mechanisms directly acting on BRCA1/2. Finally, functional HR status was strongly associated with COSMIC single base substitution signature 3, but not BRCA1/2 mutation status. Thus, the majority of BRCA1/2-mutant cell lines do not represent a suitable model for HRD. Moreover, exclusively determining BRCA1/2 mutation status may not suffice for platinum-based chemotherapy or PARPi patient selection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels

Author

Jongbloed, Elisabeth M., primary, Jansen, Maurice P.H.M., additional, de Weerd, Vanja, additional, Helmijr, Jean A., additional, Beaufort, Corine M., additional, Reinders, Marcel J. T., additional, Marion, Ronald van, additional, IJcken, Wilfred F. J. van, additional, Sonke, Gabe S., additional, Konings, Inge R. H. M., additional, Jager, Agnes, additional, Martens, John W.M., additional, Wilting, Saskia M., additional, and Makrodimitris, Stavros, additional

Published
2023
Full Text
View/download PDF

6. Abstract 5715: Circulating tumor DNA in colorectal cancer patients with resectable liver metastases: Preliminary results of the MIRACLE study

Author

Wullaert, Lissa, primary, Jansen, Maurice P., additional, Kraan, Jaco, additional, van Rees, Jan M., additional, Beaufort, Corine M., additional, Meyer, Yannick M., additional, Galjart, Boris, additional, Nierop, Pieter M., additional, Buisman, Florian E., additional, Höppener, Diederik J., additional, van der Stok, Erik P., additional, Motta, Gianmarco, additional, Grünhagen, Dirk J., additional, Verheul, Henk M., additional, Sleijfer, Stefan, additional, Wilting, Saskia M., additional, Verhoef, Cornelis, additional, and Martens, John W., additional

Published
2023
Full Text
View/download PDF

7. Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer

Author

Eyck, Ben M, primary, Jansen, Maurice PHM, additional, Noordman, Bo Jan, additional, Atmodimedjo, Peggy N, additional, van der Wilk, Berend J, additional, Martens, John WM, additional, Helmijr, Jean A, additional, Beaufort, Corine M, additional, Mostert, Bianca, additional, Doukas, Michail, additional, Wijnhoven, Bas PL, additional, Lagarde, Sjoerd M, additional, van Lanschot, J Jan B, additional, and Dinjens, Winand NM, additional

Published
2022
Full Text
View/download PDF

8. Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer.

Author

Eyck, Ben M, Jansen, Maurice PHM, Noordman, Bo Jan, Atmodimedjo, Peggy N, van der Wilk, Berend J, Martens, John WM, Helmijr, Jean A, Beaufort, Corine M, Mostert, Bianca, Doukas, Michail, Wijnhoven, Bas PL, Lagarde, Sjoerd M, van Lanschot, J Jan B, and Dinjens, Winand NM

Subjects
CIRCULATING tumor DNA, CELL-free DNA, ESOPHAGEAL cancer, RECTAL cancer, PATIENT selection, CHEMORADIOTHERAPY, POLYMERASE chain reaction
Abstract

Active surveillance instead of standard surgery after neoadjuvant chemoradiotherapy (nCRT) has been proposed for patients with oesophageal cancer. Circulating tumour DNA (ctDNA) may be used to facilitate selection of patients for surgery. We show that detection of ctDNA after nCRT seems highly suggestive of major residual disease. Tumour biopsies and blood samples were taken before, and 6 and 12 weeks after, nCRT. Biopsies were analysed with regular targeted next‐generation sequencing (NGS). Circulating cell‐free DNA (cfDNA) was analysed using targeted NGS with unique molecular identifiers and digital polymerase chain reaction. cfDNA mutations matching pre‐treatment biopsy mutations confirmed the presence of ctDNA. In total, 31 patients were included, of whom 24 had a biopsy mutation that was potentially detectable in cfDNA (77%). Pre‐treatment ctDNA was detected in nine of 24 patients (38%), four of whom had incurable disease progression before surgery. Pre‐treatment ctDNA detection had a sensitivity of 47% (95% CI 24–71) (8/17), specificity of 85% (95% CI 42–99) (6/7), positive predictive value (PPV) of 89% (95% CI 51–99) (8/9), and negative predictive value (NPV) of 40% (95% CI 17–67) (6/15) for detecting major residual disease (>10% residue in the resection specimen or progression before surgery). After nCRT, ctDNA was detected in three patients, two of whom had disease progression. Post‐nCRT ctDNA detection had a sensitivity of 21% (95% CI 6–51) (3/14), specificity of 100% (95% CI 56–100) (7/7), PPV of 100% (95% CI 31–100) (3/3), and NPV of 39% (95% CI 18–64) (7/18) for detecting major residual disease. The addition of ctDNA to the current set of diagnostics did not lead to more patients being clinically identified with residual disease. These results indicate that pre‐treatment and post‐nCRT ctDNA detection may be useful in identifying patients at high risk of disease progression. The addition of ctDNA analysis to the current set of diagnostic modalities may not improve detection of residual disease after nCRT. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

9. The Prognostic and Predictive Value of ESR1 Fusion Gene Transcripts in Primary Breast Cancer

Author

Vitale, Silvia R., primary, Ruigrok-Ritstier, Kirsten, additional, Timmermans, A. Mieke, additional, Foekens, Renée, additional, Trapman-Jansen, Anita M.A.C., additional, Beaufort, Corine M., additional, Vigneri, Paolo, additional, Sleijfer, Stefan, additional, Martens, John W.M., additional, Sieuwerts, Anieta M., additional, and Jansen, Maurice P.H.M., additional

Published
2021
Full Text
View/download PDF

10. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells

Author

Mout, Lisanne, primary, van Dessel, Lisanne F., additional, Kraan, Jaco, additional, de Jong, Anouk C., additional, Neves, Rui P.L., additional, Erkens-Schulze, Sigrun, additional, Beaufort, Corine M., additional, Sieuwerts, Anieta M., additional, van Riet, Job, additional, Woo, Thomas L.C., additional, de Wit, Ronald, additional, Sleijfer, Stefan, additional, Hamberg, Paul, additional, Sandberg, Yorick, additional, te Boekhorst, Peter A.W., additional, van de Werken, Harmen J.G., additional, Martens, John W.M., additional, Stoecklein, Nikolas H., additional, van Weerden, Wytske M., additional, and Lolkema, Martijn P., additional

Published
2021
Full Text
View/download PDF

11. TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer

Author

Vitale, Silvia R., primary, Groenendijk, Floris H., additional, van Marion, Ronald, additional, Beaufort, Corine M., additional, Helmijr, Jean C., additional, Jan Dubbink, Hendrikus, additional, N. M. Dinjens, Winand, additional, Ewing-Graham, Patricia C., additional, Smolders, Ramon, additional, van Doorn, Helena C., additional, Boere, Ingrid A., additional, Berns, Els M. J. J., additional, Helleman, Jozien, additional, and Jansen, Maurice P. H. M., additional

Published
2020
Full Text
View/download PDF

12. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer

Author

Belderbos, Bodine P.S., primary, Sieuwerts, Anieta M., additional, Hoop, Esther Oomen-de, additional, Mostert, Bianca, additional, Kraan, Jaco, additional, Hamberg, Paul, additional, Van, Mai N., additional, Beaufort, Corine M., additional, Onstenk, Wendy, additional, van Soest, Robert J., additional, Martens, John, additional, Sleijfer, Stefan, additional, de Wit, Ronald, additional, Mathijssen, Ron H.J., additional, and Lolkema, Martijn P., additional

Published
2019
Full Text
View/download PDF

13. AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel

Author

Sieuwerts, Anieta M., primary, Onstenk, Wendy, additional, Kraan, Jaco, additional, Beaufort, Corine M., additional, Van, Mai, additional, De Laere, Bram, additional, Dirix, Luc Y., additional, Hamberg, Paul, additional, Beeker, Aart, additional, Meulenbeld, Hielke J., additional, Creemers, Geert‐Jan, additional, Weerden, Wytske M., additional, Jenster, Guido W., additional, Nieuweboer, Annemieke J. M., additional, Mathijssen, Ron H. J., additional, Wit, Ronald, additional, Martens, John W. M., additional, and Sleijfer, Stefan, additional

Published
2019
Full Text
View/download PDF

14. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer

Author

Agahozo, Marie Colombe, primary, Sieuwerts, Anieta M, additional, Doebar, S Charlane, additional, Verhoef, Esther I, additional, Beaufort, Corine M, additional, Ruigrok-Ritstier, Kirsten, additional, de Weerd, Vanja, additional, Sleddens, Hein F B M, additional, Dinjens, Winand N M, additional, Martens, John W M, additional, and van Deurzen, Carolien H M, additional

Published
2019
Full Text
View/download PDF

15. An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells

Author

Sieuwerts, Anieta M., primary, Mostert, Bianca, additional, van der Vlugt-Daane, Michelle, additional, Kraan, Jaco, additional, Beaufort, Corine M., additional, Van, Mai, additional, Prager, Wendy J.C., additional, De Laere, Bram, additional, Beije, Nick, additional, Hamberg, Paul, additional, Westgeest, Hans M., additional, Tascilar, Metin, additional, Dirix, Luc Y., additional, Onstenk, Wendy, additional, de Wit, Ronald, additional, Lolkema, Martijn P., additional, Mathijssen, Ron H.J., additional, Martens, John W.M., additional, and Sleijfer, Stefan, additional

Published
2018
Full Text
View/download PDF

16. Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA

Author

Weerts, Marjolein J. A., primary, van Marion, Ronald, additional, Helmijr, Jean C. A., additional, Beaufort, Corine M., additional, Krol, Niels M. G., additional, Trapman-Jansen, Anita M. A. C., additional, Dinjens, Winand N. M., additional, Sleijfer, Stefan, additional, Jansen, Maurice P. H. M., additional, and Martens, John W. M., additional

Published
2017
Full Text
View/download PDF

17. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases

Author

Beije, Nick, primary, Helmijr, Jean C., additional, Weerts, Marjolein J.A., additional, Beaufort, Corine M., additional, Wiggin, Matthew, additional, Marziali, Andre, additional, Verhoef, Cornelis, additional, Sleijfer, Stefan, additional, Jansen, Maurice P.H.M., additional, and Martens, John W.M., additional

Published
2016
Full Text
View/download PDF

18. Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen

Author

Jansen, Maurice P.H.M., primary, Martens, John W.M., additional, Helmijr, Jean C.A., additional, Beaufort, Corine M., additional, van Marion, Ronald, additional, Krol, Niels M.G., additional, Monkhorst, Kim, additional, Trapman-Jansen, Anita M.A.C., additional, Meijer-van Gelder, Marion E., additional, Weerts, Marjolein J.A., additional, Ramirez-Ardila, Diana E., additional, Jan Dubbink, Hendrikus, additional, Foekens, John A., additional, Sleijfer, Stefan, additional, and Berns, Els M.J.J., additional

Published
2016
Full Text
View/download PDF

19. Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes

Author

Beaufort, Corine M., primary, Helmijr, Jean C. A., additional, Piskorz, Anna M., additional, Hoogstraat, Marlous, additional, Ruigrok-Ritstier, Kirsten, additional, Besselink, Nicolle, additional, Murtaza, Muhammed, additional, van IJcken, Wilfred F. J., additional, Heine, Anouk A. J., additional, Smid, Marcel, additional, Koudijs, Marco J., additional, Brenton, James D., additional, Berns, Els M. J. J., additional, and Helleman, Jozien, additional

Published
2014
Full Text
View/download PDF

20. An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7mRNA Expression in Circulating Tumor Cells

Author

Sieuwerts, Anieta M., Mostert, Bianca, van der Vlugt-Daane, Michelle, Kraan, Jaco, Beaufort, Corine M., Van, Mai, Prager, Wendy J.C., De Laere, Bram, Beije, Nick, Hamberg, Paul, Westgeest, Hans M., Tascilar, Metin, Dirix, Luc Y., Onstenk, Wendy, de Wit, Ronald, Lolkema, Martijn P., Mathijssen, Ron H.J., Martens, John W.M., and Sleijfer, Stefan

Abstract

Recent reports have emphasized the clinical relevance of detecting AR-V7in circulating tumor cells (CTCs). Our aim was to set up a validated multicenter pipeline to measure AR-V7by quantitative RT-PCR (RT-qPCR) in RNA isolated from CellSearch-enriched CTCs to provide an AR-V7–positive or AR-V7–negative score in a clinically acceptable time range. CellSearch-enirched CTCs from patients with metastatic castration–resistant prostate cancer were characterized by RT-qPCR. After optimization, it was prospectively tested whether it was possible to report the AR-V7status within 11 days (PRELUDE study). In the range of the RNA equivalent of 0.2 to 12 VCaP cells, the CV for AR-V7was 9% (n = 37). The limit of detection was 0.3, and the limit of quantitation was 3 cells in the final RT-qPCR. No differences were observed between AR-V7data generated by five technicians or in two different laboratories. For the 45 patients in PRELUDE, 13 patients were ineligible, 22 patients were AR-V7negative, and 10 were AR-V7positive. The median time to inform the physician of the test result was 7 days (range, 2 to 11 days). This assay can establish the AR-V7status in CTCs from patients with metastatic castration–resistant prostate cancer. Furthermore, it was possible to provide an AR-V7outcome within 11 days, indicating that it may be used to choose between an anti–androgen receptor or taxane-based cabazitaxel treatment.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results